# GlaxoSmithKline FDA New Drug Application submission acceptance for daprodustat

- Link: https://www.directorstalkinterviews.com/glaxosmithkline-fda-new-drug-application-submission-acceptance-for-daprodustat/4121061370
- Published: 2022-04-19T07:22:30+01:00
- Author: Amilia Stone

**[GlaxoSmithKline](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)
plc** ([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
has announced that the US Food and Drug Administration accepted the New Drug Application
for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (
HIF-PHI), for the potential treatment of patients with anaemia of chronic kidney
disease (CKD). Daprodustat was developed based upon the unique Nobel Prize-winning
science that demonstrated how cells sense and adapt to oxygen availability. The 
FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of 1 February
2023.

The daprodustat NDA is based on positive results from the ASCEND phase III clinical
trial programme, which included five pivotal trials assessing the efficacy and safety
of daprodustat for the treatment of anaemia across the spectrum of CKD. Results 
from the key cardiovascular outcomes trials were published in the New England Journal
of Medicine in November 2021 and included non-dialysis (ASCEND-ND) and dialysis (
ASCEND-D) CKD patients. These trials demonstrated that daprodustat improved and/
or maintained haemoglobin (Hb) within the target level (10-11.5 g/dL) without increased
major adverse cardiovascular events (MACE) in the intention-to-treat (ITT) populations
in each pivotal study, when compared to the standard of care, an erythropoietin 
stimulating agent (ESA), across both non-dialysis and dialysis patient settings.

Daprodustat is currently approved in Japan as _Duvroq_ for patients with renal anaemia.
In March 2022, the European Medicines Agency (EMA) validated the marketing authorisation
application (MAA) for daprodustat, which is currently under review. Additional regulatory
filings are anticipated to continue throughout 2022.

**About the ASCEND phase III clinical trial programme**

The ASCEND programme includes five phase III trials to assess the efficacy and safety
profile of daprodustat for treating anaemia of CKD across the disease pathway. The
programme enrolled over 8,000 patients treated for up to 4.26 years. Results from
all five trials were presented at the American Society of Nephrology’s Kidney Week
2021.

Results from the two pivotal cardiovascular outcomes trials, ASCEND-ND and ASCEND-
D, which investigated patients not on dialysis and on dialysis, respectively, were
also published in the New England Journal of Medicine^([[i]](https://www.londonstockexchange.com/#_edn1))
^(,[[ii]](https://www.londonstockexchange.com/#_edn2)):

·      ASCEND-ND (Anaemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-
Non-Dialysis) enrolled 3,872 non-dialysis dependent patients with anaemia of CKD
who were either switched from the standard of care (ESA) or not currently receiving
ESA therapy to receive daprodustat or ESA control (darbepoetin alfa). Iron management
protocols were instituted across both arms of the trial. The trial met its primary
efficacy and safety endpoints. Results showed that daprodustat improved and/or maintained
Hb within the target level (10-11.5 g/dL) for these patients, and the primary safety
analysis of the ITT population showed that daprodustat achieved non-inferiority 
of MACE compared to ESA control.

·      ASCEND-D (Anaemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-
Dialysis) enrolled 2,964 dialysis patients with anaemia of CKD who were switched
to receive daprodustat or ESA control from a standard of care ESA therapy. A uniform
iron management protocol was instituted across both arms of the trial. The trial
met its primary efficacy and safety endpoints. Results showed daprodustat improved
or maintained Hb within target levels (10-11.5 g/dL) for these patients, and the
primary safety analysis of the ITT population showed that daprodustat achieved non-
inferiority of MACE compared to ESA control.

**About daprodustat**

Daprodustat, a HIF-PHI, belongs to a novel class of oral medicines indicated for
the potential treatment of anaemia of CKD in adult patients not on dialysis and 
on dialysis. Inhibition of oxygen-sensing prolyl hydroxylase enzymes stabilises 
hypoxia-inducible factors, which can lead to transcription of erythropoietin and
other genes involved in the correction of anaemia, similar to the physiological 
effects that occur in the human body at high altitude. Daprodustat has been developed
to provide a convenient oral treatment option for patients with anaemia of CKD.

_GlaxoSmithKline is a science-led global healthcare company._

Share on:
